RadNet, Inc. (RDNT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2.61%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 2.61% | Share-based compensation / revenue. Period ending 2026-06-30. $59.28M ÷ $2.27B × 100 ≈ 2.61% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 2.27B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 59.28M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 70.78M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.27B | $59.28M | $70.78M | (m) | (m) | 2.61% | (m) | (m) |
| 2026-03-31 | (m) | $2.14B | $57.48M | $62.19M | (m) | (m) | 2.68% | (m) | (m) |
| 2025-12-31 | (m) | $2.04B | $54.60M | $61.99M | (m) | (m) | 2.68% | (m) | (m) |
| 2025-09-30 | (m) | $1.97B | $54.74M | $58.69M | (m) | (m) | 2.78% | (m) | (m) |
| 2025-06-30 | (m) | $1.91B | $50.42M | $65.21M | (m) | (m) | 2.64% | (m) | (m) |
| 2025-03-31 | (m) | $1.87B | $46.43M | $69.18M | (m) | (m) | 2.48% | (m) | (m) |
| 2024-12-31 | (m) | $1.83B | $29.83M | $104.62M | (m) | (m) | 1.63% | (m) | (m) |
| 2024-09-30 | (m) | $1.77B | $26.77M | $104.43M | (m) | (m) | 1.51% | (m) | (m) |
| 2024-06-30 | (m) | $1.71B | $26.38M | $113.77M | (m) | (m) | 1.54% | (m) | (m) |
| 2024-03-31 | (m) | $1.66B | $26.50M | $103.36M | (m) | (m) | 1.60% | (m) | (m) |
| 2023-12-31 | (m) | $1.62B | $26.79M | $98.70M | (m) | (m) | 1.66% | (m) | (m) |
| 2023-09-30 | (m) | $1.58B | $26.04M | $95.97M | (m) | (m) | 1.65% | (m) | (m) |
| 2023-06-30 | (m) | $1.53B | $25.03M | $59.64M | (m) | (m) | 1.64% | (m) | (m) |
| 2023-03-31 | (m) | $1.48B | $24.85M | $54.75M | (m) | (m) | 1.68% | (m) | (m) |
| 2022-12-31 | (m) | $1.43B | $23.77M | $46.36M | (m) | (m) | 1.66% | (m) | (m) |
| 2022-09-30 | (m) | $1.38B | $22.75M | $29.41M | (m) | (m) | 1.65% | (m) | (m) |
| 2022-06-30 | (m) | $1.36B | $23.85M | $55.06M | (m) | (m) | 1.75% | (m) | (m) |
| 2022-03-31 | (m) | $1.34B | $28.06M | $63.18M | (m) | (m) | 2.09% | (m) | (m) |
| 2021-12-31 | (m) | $1.32B | $25.20M | $82.55M | (m) | (m) | 1.92% | (m) | (m) |
| 2021-09-30 | (m) | $1.29B | $23.83M | $98.81M | (m) | (m) | 1.85% | (m) | (m) |
| 2021-06-30 | (m) | $1.25B | $21.47M | $89.61M | (m) | (m) | 1.72% | (m) | (m) |
| 2021-03-31 | (m) | $1.11B | $14.03M | $62.11M | (m) | (m) | 1.27% | (m) | (m) |
| 2020-12-31 | (m) | $1.07B | $12.40M | $35.68M | (m) | (m) | 1.16% | (m) | (m) |
| 2020-09-30 | (m) | $938.80M | $11.91M | $38.55M | (m) | (m) | 1.27% | (m) | (m) |
| 2020-06-30 | (m) | $939.72M | $11.23M | $32.03M | (m) | (m) | 1.19% | (m) | (m) |
| 2020-03-31 | (m) | $1.04B | $10.81M | $53.83M | (m) | (m) | 1.04% | (m) | (m) |
| 2019-12-31 | (m) | $1.03B | $8.73M | $69.88M | (m) | (m) | 0.85% | (m) | (m) |
| 2019-09-30 | (m) | $1.11B | $8.07M | $45.56M | (m) | (m) | 0.73% | (m) | (m) |
| 2019-06-30 | (m) | $1.06B | $8.35M | $45.16M | (m) | (m) | 0.79% | (m) | (m) |
| 2019-03-31 | (m) | $1.02B | $8.46M | $39.04M | (m) | (m) | 0.83% | (m) | (m) |
| 2018-12-31 | (m) | $975.15M | $7.66M | $30.89M | (m) | (m) | 0.79% | (m) | (m) |
| 2018-09-30 | (m) | (m) | $7.50M | $49.73M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $7.36M | $44.12M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $7.26M | $42.41M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $922.19M | $6.79M | $50.05M | (m) | (m) | 0.74% | (m) | (m) |
| 2017-09-30 | (m) | $911.57M | $6.75M | $21.77M | (m) | (m) | 0.74% | (m) | (m) |
| 2017-06-30 | (m) | $908.61M | $6.38M | $23.38M | (m) | (m) | 0.70% | (m) | (m) |
| 2017-03-31 | (m) | $897.16M | $6.37M | $17.30M | (m) | (m) | 0.71% | (m) | (m) |
| 2016-12-31 | (m) | $884.53M | $5.83M | $38.48M | (m) | (m) | 0.66% | (m) | (m) |
| 2016-09-30 | (m) | $875.30M | $6.09M | $8.06M | (m) | (m) | 0.70% | (m) | (m) |
| 2016-06-30 | (m) | $859.02M | $5.84M | $12.84M | (m) | (m) | 0.68% | (m) | (m) |
| 2016-03-31 | (m) | $844.75M | $6.83M | $18.14M | (m) | (m) | 0.81% | (m) | (m) |
| 2015-12-31 | (m) | $809.63M | $7.65M | $39.12M | (m) | (m) | 0.94% | (m) | (m) |
| 2015-09-30 | (m) | (m) | $6.91M | $960.00K | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $755.17M | $6.43M | $-1.03M | (m) | (m) | 0.85% | (m) | (m) |
| 2015-03-31 | (m) | $729.96M | $5.03M | $1.23M | (m) | (m) | 0.69% | (m) | (m) |
| 2014-12-31 | (m) | $717.57M | $2.50M | $53.30M | (m) | (m) | 0.35% | (m) | (m) |
| 2014-09-30 | (m) | (m) | $2.60M | $20.16M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $2.63M | $13.51M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $2.65M | $10.85M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $702.99M | $2.57M | $43.60M | (m) | (m) | 0.37% | (m) | (m) |
| 2013-09-30 | (m) | $121.86M | $2.64M | $3.98M | (m) | (m) | 2.17% | (m) | (m) |
| 2013-06-30 | (m) | (m) | $2.61M | $9.23M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $2.51M | $9.71M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $85.04M | $2.74M | $45.23M | (m) | (m) | 3.22% | (m) | (m) |
| 2012-09-30 | (m) | (m) | $2.75M | $53.70M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $660.42M | $3.03M | $50.84M | (m) | (m) | 0.46% | (m) | (m) |
| 2012-03-31 | (m) | $642.76M | $3.24M | $53.01M | (m) | (m) | 0.50% | (m) | (m) |
| 2011-12-31 | (m) | $619.80M | $3.11M | $50.66M | (m) | (m) | 0.50% | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $551.82M | $3.72M | $41.71M | (m) | (m) | 0.67% | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $527.62M | $3.61M | $42.10M | (m) | (m) | 0.68% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |